Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the ...

For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reductio ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

Eli Lilly's tirzepatide cut cardiovascular mortality and heart failure event risk by 38% in HFpEF patients over a two-year ...

The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

The 503A facilities are also producing compounded semaglutide and tirzepatide for hundreds of thousands of patients.

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?